The Protocol Specific Research Support (PSRS) of the UNM Cancer Center functions to support early phase investigator-initiated pilot studies that lack sponsored support. Early phase unsupported investigator-initiated clinical trials are proposed at the Clinical Working Group level, and reviewed by the Protocol Review Committee (at UNM termed the Medical and Scientific Review Committee) for scientific merit. Should they be approved at this level, and lack support, they are submitted to the Clinical Research Committee for consideration of institutional support. This PSRS review is chaired by C. Verschraegen, MD, the member of the Clinical Research Committee responsible for organizing PSRS evaluations. Should the unsupported protocols be deemed worthy of support, they are then submitted to an appropriate IRB, and if approved, implemented by the Clinical Protocol, Data Management, and Informatics Shared Resource with protocol specific financial support. The PSRS research nurse is M. Pruess, and the data manager is M. Allred. In FY 2008/9 there were 19 investigator-initiated Phase l-lll interventional clinical trials that required UNM Cancer Center support. These trials accrued 222 total patients in the FY 2008/9. In FY 2008/9 there were 11 investigator-initiated phase I or l/ll interventional clinical trials that were supported by the UNM Cancer Center. These trials accrued 52 total patients. These trials were innovative pilot projects that were designed to lead to larger externally supported later phase clinical trials. This significant UNM Cancer Center support of early phase investigator-initiated clinical trials demonstrates an active Protocol Specific Research Support program.

Public Health Relevance

Developing effective new cancer therapies is important since the survival of many patients with cancer is still poor. Not all new therapies are financially supported, especially those developed individually by UNM Cancer Center clinical investigators. The Protocol Specific Research support mechanism provides support for new cancer treatments that have no other financial support. This increases the number of new treatments that can be tested here.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of New Mexico Health Sciences Center
United States
Zip Code
Kuehl, Philip J; Grimes, Marcie J; Dubose, Devon et al. (2018) Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model. Drug Deliv 25:1127-1136
Köbel, Martin; Luo, Li; Grevers, Xin et al. (2018) Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. Int J Gynecol Pathol :
Bredemeyer, Andrea L; Edwards, Bruce S; Haynes, Mark K et al. (2018) High-Throughput Screening Approach for Identifying Compounds That Inhibit Nonhomologous End Joining. SLAS Discov 23:624-633
Orlow, Irene; Shi, Yang; Kanetsky, Peter A et al. (2018) The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival. Pigment Cell Melanoma Res 31:287-296
Sharma, Geetanjali; Mauvais-Jarvis, Franck; Prossnitz, Eric R (2018) Roles of G protein-coupled estrogen receptor GPER in metabolic regulation. J Steroid Biochem Mol Biol 176:31-37
Perez, Dominique R; Edwards, Bruce S; Sklar, Larry A et al. (2018) High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis Software, SynScreen. SLAS Discov 23:751-760
Deretic, Vojo; Prossnitz, Eric; Burge, Mark et al. (2018) Autophagy, Inflammation, and Metabolism (AIM) Center of Biomedical Research Excellence: supporting the next generation of autophagy researchers and fostering international collaborations. Autophagy 14:925-929
Hill, Deirdre A; Friend, Sarah; Lomo, Lesley et al. (2018) Breast cancer survival, survival disparities, and guideline-based treatment. Breast Cancer Res Treat 170:405-414
Guo, Yan; Yu, Hui; Wang, Jing et al. (2018) The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. Genes (Basel) 9:
Hatch, Ellen W; Geeze, Mary Beth; Martin, Cheyenne et al. (2018) Variability of PD-L1 expression in mastocytosis. Blood Adv 2:189-199

Showing the most recent 10 out of 344 publications